Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients.
Koralkova P, Belickova M, Kundrat D, Dostalova Merkerova M, Krejcik Z, Szikszai K, Kaisrlikova M, Vesela J, Vyhlidalova P, Stetka J, Hlavackova A, Suttnar J, Flodr P, Stritesky J, Jonasova A, Cermak J, Divoky V. Koralkova P, et al. Among authors: vesela j. Cancers (Basel). 2021 Apr 30;13(9):2161. doi: 10.3390/cancers13092161. Cancers (Basel). 2021. PMID: 33946220 Free PMC article.
TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes.
Belickova M, Vesela J, Jonasova A, Pejsova B, Votavova H, Merkerova MD, Zemanova Z, Brezinova J, Mikulenkova D, Lauermannova M, Valka J, Michalova K, Neuwirtova R, Cermak J. Belickova M, et al. Among authors: vesela j. Oncotarget. 2016 Jun 14;7(24):36266-36279. doi: 10.18632/oncotarget.9200. Oncotarget. 2016. PMID: 27167113 Free PMC article.
Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms.
Mambet C, Babosova O, Defour JP, Leroy E, Necula L, Stanca O, Tatic A, Berbec N, Coriu D, Belickova M, Kralova B, Lanikova L, Vesela J, Pecquet C, Saussoy P, Havelange V, Diaconu CC, Divoky V, Constantinescu SN. Mambet C, et al. Among authors: vesela j. Blood. 2018 Dec 20;132(25):2695-2699. doi: 10.1182/blood-2018-04-843060. Epub 2018 Oct 30. Blood. 2018. PMID: 30377194 Free article. No abstract available.
Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution.
Svobodova K, Lhotska H, Hodanova L, Pavlistova L, Vesela D, Belickova M, Vesela J, Brezinova J, Sarova I, Izakova S, Lizcova L, Siskova M, Jonasova A, Cermak J, Michalova K, Zemanova Z. Svobodova K, et al. Among authors: vesela d, vesela j. Genes Chromosomes Cancer. 2020 Jul;59(7):396-405. doi: 10.1002/gcc.22841. Epub 2020 Mar 25. Genes Chromosomes Cancer. 2020. PMID: 32170980
Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome.
Hrustincova A, Krejcik Z, Kundrat D, Szikszai K, Belickova M, Pecherkova P, Klema J, Vesela J, Hruba M, Cermak J, Hrdinova T, Krijt M, Valka J, Jonasova A, Merkerova MD. Hrustincova A, et al. Among authors: vesela j. Cells. 2020 Mar 26;9(4):794. doi: 10.3390/cells9040794. Cells. 2020. PMID: 32224889 Free PMC article.
87 results